<?xml version="1.0"?>
<tei xml:space="preserve">
	<teiHeader>
		<fileDesc xml:id="0"/>
	</teiHeader>
	<text xml:lang="en">
			<front>Organocatalytic Synthesis of Spiro-Bridged Heterocyclic <lb/>Compounds via a Chemoselective Vinylogous Michael/Cyclization/ <lb/>Rearrangement Sequence <lb/>I-Ting Chen, Hsuan Lin, and Jeng-Liang Han* <lb/>Cite This: https://doi.org/10.1021/acs.joc.5c00443 <lb/>Read Online <lb/>ACCESS <lb/>Metrics &amp; More <lb/>Article Recommendations <lb/>* sı Supporting Information <lb/>ABSTRACT: An organocatalytic cascade reaction of 2-ethylidene <lb/>1,3-indandiones and isatylidene-malononitriles has been achieved <lb/>using quinine as the catalyst. The unexpected vinylogous Michael <lb/>addition at the β position of isatylidene-malononitriles, followed by <lb/>aldol cyclization, 1,2-addition of alkoxide to nitrile, and [1,3]-O-to-<lb/>N rearrangement, leads to the generation of unique spiro-bridged <lb/>heterocyclic compounds containing amide, indanone, and oxindole <lb/>moieties in good to excellent yields with high diastereoselectivity. <lb/></front>

			<body>O xindole alkaloids are an important group of mono-<lb/>terpene alkaloids with spirocyclic oxindole nuclei and are <lb/>often associated with significant pharmacological activity. 1,2 <lb/>Among these, spiro-bridged oxindole frameworks are core <lb/>structures widely encountered in many natural products <lb/>(Figure 1). For example, chitsenine I and alkaloid II exhibit <lb/>short-lived inhibitory activity in vivo of ganglionic transmission <lb/>in both rats and rabbits. 3 Spiro-bridged oxindole III, prepared <lb/>by Sakai and co-workers as an analogue of II, has been <lb/>employed in a formulation known to inhibit ulcers. 4 On the <lb/>other hand, gelsemine IV is a spiro-bridged oxindole alkaloid <lb/>isolated from flowering plants of the genus Gelsemium and <lb/>exhibited potent and specific antinociception in chronic pain <lb/>by acting at the three spinal glycine receptors. 5 <lb/>The combinatorial pharmacophore strategy has played a <lb/>central role in the search of leading compounds for new drug <lb/>development. 6 Oxindole, 7 indanone, 8 and amide 9 fragments <lb/>are three well-known pharmacophores and are found in various <lb/>natural and bioactive molecules (Figure 2). However, most <lb/>established protocols furnish the products containing only <lb/>oxindole and indanone pharmacophores in spiro-fused <lb/>heterocyclic systems. 10 To the best of our knowledge, there <lb/>have been no reports on the construction of compounds <lb/>combining all of them in one spiro-bridged heterocyclic <lb/>molecule, which may potentially have biological activities. <lb/>Hence, it is highly desirable to develop efficient synthetic <lb/></body>

			<front>Received: February 26, 2025 <lb/>Revised: April 25, 2025 <lb/>Accepted: May 7, 2025 <lb/></front>

			<body>Figure 1. Selected natural products containing a spiro-bridged <lb/>oxindole moiety. <lb/>Figure 2. Selected compounds containing oxindole and indanone <lb/>moieties. <lb/></body>

			<front>Note <lb/>pubs.acs.org/joc <lb/>© XXXX The Authors. Published by <lb/>American Chemical Society <lb/>A <lb/>https://doi.org/10.1021/acs.joc.5c00443 <lb/>J. Org. Chem. XXXX, XXX, XXX-XXX <lb/>This article is licensed under CC-BY 4.0 <lb/>Downloaded via UNIV OF PENNSYLVANIA on May 27, 2025 at 23:46:29 (UTC). <lb/>See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles. <lb/></front>

			<body>procedures for the synthesis of spiro-bridged heterocyclic <lb/>compounds containing these three potential pharmacophores. <lb/>Isatylidene-malononitriles, which are a class of α,α-<lb/>dicyanoolefins, have been widely employed as versatile <lb/>acceptors or dienophiles in various reactions. 11 In the past <lb/>few years, significant progress has been made in the <lb/>development of organocatalyzed annulation reactions using <lb/>isatylidene-malononitriles as electrophiles by a number of <lb/>publications in the literature. 12 In this regard, the annulation <lb/>reactions are known to take place exclusively at the α position <lb/>first by nucleophilic addition, and then electrophilic sites are <lb/>attacked from the β position (Scheme 1a, path A). In contrast, <lb/>the annulation reactions take place exclusively at the β position <lb/>first by nucleophilic addition, and then electrophilic sites are <lb/>attacked from the α position, which remains rare (Scheme 1a, <lb/>path B). Recently, Namboothiri and co-workers reported a <lb/>vinylogous Michael addition of nitroalkylideneoxindoles to <lb/>isatylidene-malononitriles in the regioselective synthesis of <lb/>dispirocyclopentylbisoxindoles. 13 To the best of our knowl-<lb/>edge, this is the only example of nucleophilic addition to <lb/>isatylidene-malononitriles at the β position first. Hence, <lb/>inspired by the work mentioned above, we envisioned that <lb/>2-ethylidene 1,3-indandiones 2 will also proceed via vinylogous <lb/>Michael addition at the β position of isatylidene-malononitriles <lb/>1 to the construction of spirooxindoles with an indandione <lb/>moiety. However, we found that the obtained products <lb/>contained amide, indanone, and oxindole moieties. Moreover, <lb/>we discovered that the amide group formed via a [1,3]-O-to-N <lb/>rearrangement of allylic imidates A. 14 It is interesting because <lb/>this type of rearrangement usually has been accomplished in <lb/>the presence of a Lewis acid catalyst. 15 The base-catalyzed <lb/>[1,3]-O-to-N rearrangement is underexplored. Continuing our <lb/>efforts to develop efficient vinylogous reactions with 2-<lb/>ethylidene indane-1,3-diones, 16 we herein report the successful <lb/>execution of an unusual cascade reaction to establish unique <lb/>spiro-bridged heterocyclic compounds containing amide, <lb/>indanone, and oxindole moieties. <lb/>At the outset of the investigation, the reaction between 2-<lb/>ethylidene 1,3-indandione 1a and isatylidene-malononitrile 2a <lb/>was employed as the model reaction for optimization (Table <lb/>1). First, several inorganic bases were evaluated in CH 2 Cl 2 , and <lb/>all of them yielded moderate results (entries 1-3). <lb/>Subsequently, various organic bases were used to catalyze the <lb/>reaction. However, both the yield and diastereoselectivity were <lb/>lower than those of inorganic bases (entries 4-6). To our <lb/>delight, quinine, which forms one hydrogen bond between <lb/>reactants, delivered the product with the highest yield and <lb/>good diastereoselectivity (entry 7). The investigations of <lb/>various solvents showed that THF gave a similar diaster-<lb/>eoselectivity and a better product yield (entries 8-11). <lb/>Upon treatment of the reaction mixture with different <lb/>concentrations, 0.1 M was identified as the best concentration <lb/>to promote diastereoselectivity with a slightly increased yield <lb/>(entries 12-14). Reducing the amount of base resulted in a <lb/>decreased yield (entry 15). Finally, the optimal conditions <lb/>were selected by conducting the reaction at room temperature <lb/>in THF with 20 mol % quinine at a substrate concentration of <lb/>0.1 M (entry 13). <lb/>With the optimal conditions established, we next examined <lb/>the scope of various isatylidene-malononitriles 1 and 2-<lb/>ethylidene 1,3-indandiones 2. As depicted in Scheme 2, all <lb/>reactions proceeded well under the described conditions, <lb/>affording the desired products in moderate to high isolated <lb/>yields with excellent levels of diastereoselectivity. First, the <lb/>positions and electronic properties of isatin substituents were <lb/>tested. <lb/>Notably, the 5-F-and 7-F-substituted isatylidene-malononi-<lb/>triles gave lower yields of products 3b (69%) and 3j (54%), <lb/>respectively. The lower reactivity of fluoro-substituted <lb/>isatylidene-malononitriles was observed. It is possible that <lb/>the fluorine atom generates hydrogen bonding with the catalyst <lb/>and retards the turnover efficiency of the catalyst. <lb/>Scheme 1. Site Selectivity of Isatylidene-malononitriles <lb/>Table 1. Optimization of the Reaction Conditions a <lb/>entry <lb/>base <lb/>solvent <lb/>yield (%) b <lb/>dr c <lb/>1 <lb/>K 2 CO 3 <lb/>CH 2 Cl 2 <lb/>62 <lb/>&gt;20:1 <lb/>2 <lb/>K 3 PO 4 <lb/>CH 2 Cl 2 <lb/>56 <lb/>&gt;20:1 <lb/>3 <lb/>NaOH <lb/>CH 2 Cl 2 <lb/>58 <lb/>&gt;20:1 <lb/>4 <lb/>DABCO <lb/>CH 2 Cl 2 <lb/>52 <lb/>7:1 <lb/>5 <lb/>Et 3 N <lb/>CH 2 Cl 2 <lb/>50 <lb/>11:1 <lb/>6 <lb/>DMAP <lb/>CH 2 Cl 2 <lb/>52 <lb/>12:1 <lb/>7 <lb/>quinine <lb/>CH 2 Cl 2 <lb/>87 <lb/>17:1 <lb/>8 <lb/>quinine <lb/>toluene <lb/>88 <lb/>15:1 <lb/>9 <lb/>quinine <lb/>THF <lb/>92 <lb/>16:1 <lb/>10 <lb/>quinine <lb/>EA <lb/>83 <lb/>&gt;20:1 <lb/>11 <lb/>quinine <lb/>CH 3 CN <lb/>51 <lb/>11:1 <lb/>12 d <lb/>quinine <lb/>THF <lb/>91 <lb/>&gt;20:1 <lb/>13 e <lb/>quinine <lb/>THF <lb/>93 <lb/>&gt;20:1 <lb/>14, f <lb/>quinine <lb/>THF <lb/>80 <lb/>&gt;20:1 <lb/>15 e,g <lb/>quinine <lb/>THF <lb/>85 <lb/>&gt;20:1 <lb/>a Unless otherwise noted, the reaction was carried out by using 0.15 <lb/>mmol of 2a, 0.1 mmol of 1a, and 20 mol % base in 0.25 mL of solvent <lb/>at RT (25 °C) for 48 h. b Isolated yield. c Detemined by NMR analysis <lb/>of the crude mixture. d With 0.5 mL of THF. e With 1.0 mL of THF. <lb/>f With 2.0 mL of THF. g With 10 mol % base. <lb/></body>
				
			<note place="headnote">The Journal of Organic Chemistry <lb/> pubs.acs.org/joc <lb/>Note <lb/></note>

			<note place="footnote">https://doi.org/10.1021/acs.joc.5c00443 <lb/>J. Org. Chem. XXXX, XXX, XXX-XXX <lb/></note>

			<page>B <lb/></page>

			<body>Indandione 2a could react with electron-rich and electron-<lb/>deficient isatylidene-malononitriles and provided products 3c-<lb/>i in high yields (80-90%) with high diastereoselectivity <lb/>(&gt;20:1). The scale-up reaction for 1h and 2a also proceeded <lb/>smoothly to give product 3h in 74% isolated yield and &gt;20:1 <lb/>dr. This result is also similar to the small-scale reaction. <lb/>Subsequent investigations then focused on the different aryl <lb/>substitutions on 2-ethylidene 1,3-indandiones 2. In all cases, <lb/>the reactions proceeded well, affording 3k-q in good to high <lb/>yields (68-91%) and excellent stereoselectivities (&gt;20:1 dr). <lb/>Furthermore, the effect of protecting groups of isatylidene-<lb/>malononitriles 1 was also investigated, leading to the formation <lb/>of products 3r-3v with excellent diastereoselectivity (&gt;20:1). <lb/>However, complex mixtures were observed without protection <lb/>or when the protecting group was replaced with an electron-<lb/>withdrawing group (Boc) (3w and 3x). The structure of 3 was <lb/>confirmed using single-crystal X-ray diffraction analysis of 3f <lb/>(CCDC 2370395). 17 <lb/>We then carried out the functionalization of product 3h. <lb/>Treatment of 3h with Boc 2 O under basic conditions resulted in <lb/>the protection of amide and ketone groups, leading to the <lb/>formation of di-Boc-protected product 4 in 75% reaction yield <lb/>(Scheme 3a). The protection of ketone was unexpected, and it <lb/>might be from the deprotonation of the γ position of the <lb/>ketone by a base. To prove this, we then performed a <lb/>deuterium labeling study under basic conditions and obtained <lb/>product 3h-d 2 in 69% yield with 76% deuterium labeling <lb/>(Scheme 3b). <lb/>On the basis of previous work 12,13 and a deuterium labeling <lb/>study (Scheme 3b), a plausible catalytic cycle for the tertiary <lb/>amine-catalyzed reaction is proposed in Scheme 4. First, the <lb/>Scheme 2. Substrate Scope a <lb/>a <lb/>Reaction conditions: 0.15 mmol of 2a, 0.1 mmol of 1a, and 20 mol % <lb/>quinine in 1.0 mL of THF at RT (25 °C) for 48 h. Isolated yield. <lb/>Scheme 3. Chemical Transformation and Deuterium <lb/>Labeling of 3h <lb/>Scheme 4. Plausible Reaction Mechanism <lb/></body>

			<note place="headnote">The Journal of Organic Chemistry <lb/> pubs.acs.org/joc <lb/>Note <lb/></note>

			<note place="footnote">https://doi.org/10.1021/acs.joc.5c00443 <lb/>J. Org. Chem. XXXX, XXX, XXX-XXX <lb/></note>

			<page>C <lb/></page>

			<body>acidic hydrogen of 2-ethylidene 1,3-indandione 2a is <lb/>deprotonated by the catalyst to generate Int-1. Furthermore, <lb/>Int-1 undergoes Michael addition to the β position of <lb/>electrophile 1a, forming intermediate Int-2. Next, conjugated <lb/>electrons attack the carbonyl group of indandione to form Int-<lb/>3. The 1,2-addition of alkoxide to nitrile afforded imidate Int-4 <lb/>after protonation. Finally, the deprotonation of the γ position <lb/>of ketone by a base triggered a [1,3]-O-to-N rearrangement of <lb/>allylic imidate Int-4 and delivered product 3a. <lb/>To gain further mechanistic insights into the process, we <lb/>conducted density functional theory (DFT) calculations <lb/>performed at the M06-2X-D3/def2-TZVPP/SMD(THF)// <lb/>B3LYP/6-311G(d,p)/IEFPCM(THF) theoretical level. <lb/>In the catalytic cycles listed in Scheme 4, a comprehensive <lb/>depiction of the energy profiles for this cascade reaction is <lb/>provided in Figure 3. The structure of the catalyst was <lb/>simplified to DABCO for the following DFT calculation. The <lb/>energy of TS2, where the nucleophile adds to the β position of <lb/>1a, is lower than the energy of the nucleophile addition at the <lb/>α position of 1a (TS1). Hence, the vinylogous Michael <lb/>addition of 1,3-indandione 1a at the β position of 1a is <lb/>preferred. Enolate Int-6, which originates from the addition of <lb/>a nucleophile to the β position of 1a, then attacks the carbonyl <lb/>group of indandione with a barrier of 9.5 kcal mol -1 . The 1,2-<lb/>addition of alkoxide to nitrile afforded imidate Int-8 after <lb/>protonation. Although the deprotonation of the γ position of <lb/>ketone by a base has a higher energy barrier (14.8 kcal mol -1 ), <lb/>the barrier for the rearrangement of allylic imidate Int-9 to <lb/>amide anion Int-10 is lower than that of the deprotonation <lb/>step (10.9 kcal mol -1 ). The intramolecular aza-Michael <lb/>addition to enone to form product 3a suffers a high barrier <lb/>of 24.8 kcal mol -1 due to steric hindrance. However, product <lb/>3a is exothermically formed by 39.2 kcal mol -1 , indicating the <lb/>formation of 3a is thermodynamically favorable. <lb/>The asymmetric version of this cascade reaction was also <lb/>investigated. Preliminary screening of chiral organocatalysts <lb/>was conducted in CH 2 Cl 2 at room temperature. The <lb/>enantioselectivity and diastereoselectivity were moderate (see <lb/>the Supporting Information for more details). We have not <lb/>obtained satisfactory results so far. <lb/>In summary, we have developed an organocatalytic cascade <lb/>reaction of 2-ethylidene 1,3-indandiones 2 and isatylidene-<lb/>malononitriles 1 using quinine as the catalyst. The unexpected <lb/>vinylogous Michael addition at the β position of isatylidene-<lb/>malononitriles, followed by aldol cyclization, 1,2-addition of <lb/>alkoxide to nitrile, and [1,3]-O-to-N rearrangement, led to the <lb/>generation of unique spiro-bridged heterocyclic compounds <lb/>containing amide, indanone, and oxindole moieties in good to <lb/>excellent yields with high diastereoselectivities. The DFT <lb/>calculations were conducted to demonstrate why the vinyl-<lb/>ogous Michael addition occurred at the β position of the <lb/>isatylidene-malononitriles. <lb/>■ EXPERIMENTAL SECTION <lb/>All commercially available reagents were used without further <lb/>purification unless otherwise stated. All of the reaction solvents <lb/>were purified before use. Proton nuclear magnetic resonance ( 1 H <lb/>NMR) spectra were recorded on a commercial instrument at 400 <lb/>MHz. Carbon-13 nuclear magnetic resonance ( 13 C{ 1 H} NMR) <lb/>spectra were recorded at 100 MHz. The proton signal for a residual <lb/>nondeuterated solvent (δ 7.26 for CHCl 3 ) was used as an internal <lb/>reference for 1 H NMR spectra. For 13 C{ 1 H} NMR spectra, chemical <lb/>shifts are reported relative to the δ 77.0 resonance of CHCl 3 . <lb/>Coupling constants are reported in hertz. Melting points were <lb/>determined on a BUCHI B-545 melting point apparatus and were <lb/>uncorrected. High-resolution mass spectra were recorded on a <lb/>Thermo Fisher Scientific LTQ Orbitrap XL mass spectrometer. The <lb/>single crystal was measured by a Bruker D8 VENTURE X-ray single-<lb/>crystal diffractometer. Analytical thin-layer chromatography (TLC) <lb/>was performed on silica gel 60 F254 precoated plates with <lb/>visualization under UV light. Column chromatography was generally <lb/>performed using 40-63 μm (230-400 mesh) silica gel, typically using <lb/>a 50-100:1 weight ratio of silica gel to the crude product. Isatylidene-<lb/>malononitriles 1 and spiroindane-1,3-diones 2 were prepared <lb/>according to known procedures. 18,19 <lb/>General Procedure for the Synthesis of Compounds 3. To a <lb/>7 mL vial equipped with a stirring bar were added 1 (0.10 mmol, 1 <lb/>equiv), 2 (0.15 mmol, 1.5 equiv), and quinine (20 mol %). Then, 1.0 <lb/>mL of THF was added to the mixture, and the resulting reaction <lb/>mixture was allowed to stir at room temperature for 48 h. After <lb/>completion of the reaction as indicated by TLC, the solvent was <lb/>removed under reduced pressure and the resulting residue was <lb/>purified by column chromatography on silica gel using a hexane/ethyl <lb/>acetate eluent at 7:1 to 5:1 to 3:1 to afford 3. <lb/>Figure 3. Energy profiles for the cascade reaction of 1a and 2a catalyzed by DABCO. The relative free energies are given in kilocalories per mole. <lb/></body>

			<note place="headnote">The Journal of Organic Chemistry <lb/> pubs.acs.org/joc <lb/>Note <lb/></note>

			<note place="footnote">https://doi.org/10.1021/acs.joc.5c00443 <lb/>J. Org. Chem. XXXX, XXX, XXX-XXX <lb/></note>

			<page>D <lb/></page>

			<body>Synthesis of 3h on a 1.0 mmol Scale. To a 25 mL vial <lb/>equipped with a stirring bar were added 1h (364 mg, 1.0 mmol), 2 <lb/>(372 mg, 0.15 mmol), and quinine (65 mg, 0.2 mmol, 20 mol %). <lb/>Then, 10 mL of THF was added to the mixture, and the resulting <lb/>reaction mixture was allowed to stir at room temperature for 48 h. <lb/>After completion of the reaction as indicated by TLC, the solvent was <lb/>removed under reduced pressure and the resulting residue was <lb/>purified by column chromatography on silica gel using a hexane/ethyl <lb/>acetate eluent at 7:1 to 5:1 to 3:1 to afford 3h (453 mg, 74% yield). <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-benzyl-5′-phenyl-3′,4′-<lb/>dihydro-1′H-spiro[indoline-3,11′-[3,10b]methanoindeno[1,2-<lb/>b]azepine]-2,2′,6′-trione (3a). Following the general procedure <lb/>with 1a (28.5 mg, 0.10 mmol), 2a (37.2 mg, 0.15 mmol), and quinine <lb/>(6.8 mg, 20 mol %), the title compound was obtained as an orange <lb/>powder after purification by column chromatography on silica gel <lb/>using a hexane/ethyl acetate eluent (7:1 to 5:1 to 3:1): yield 93% <lb/>(49.6 mg); dr &gt;20:1; mp 201.5-202.5 °C; 1 H NMR (400 MHz, <lb/>CDCl 3 ) δ 7.67-7.61 (m, 4H), 7.58-7.50 (m, 4H), 7.45-7.39 (m, <lb/>2H), 7.34-7.28 (m, 3H), 7.28-7.25 (m, 2H), 7.18-7.12 (m, 2H), <lb/>6.889 (t, J = 7.7 Hz, 1H), 6.72 (d, J = 7.9 Hz, 1H), 5.05-4.96 (m, <lb/>2H), 3.60 (d, J = 20.2 Hz, 1H), 3.38 (d, J = 20.3 Hz, 1H); <lb/>13 <lb/>C{ 1 H}NMR (101 MHz, CDCl 3 ) δ 186.2, 173.3, 168.5, 148.0, 143.8, <lb/>140.6, 140.4, 136.7, 135.8, 134.7, 134.2, 131.6, 131.3, 131.0, 129.1, <lb/>129.0, 128.8, 128.64, 128.60, 128.1, 127.8, 127.63, 127.59, 125.8, <lb/>125.5, 124.7, 123.6, 119.6, 115.6, 110.3, 66.1, 61.2, 50.3, 44.4, 36.2; <lb/>HRMS (ESI) calcd for C 35 H 23 N 3 O 3 Na [M + Na] + 556.1632, found <lb/>556.1629. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-benzyl-5-fluoro-5′-phe-<lb/>nyl-3′,4′-dihydro-1′H-spiro[indoline-3,11′-[3,10b]-<lb/>methanoindeno[1,2-b]azepine]-2,2′,6′-trione (3b). Following <lb/>the general procedure with 1b (30.3 mg, 0.10 mmol), 2a (37.2 mg, <lb/>0.15 mmol), and quinine (6.8 mg, 20 mol %), the title compound was <lb/>obtained as an orange powder after purification by column <lb/>chromatography on silica gel using a hexane/ethyl acetate eluent <lb/>(7:1 to 5:1 to 3:1): yield 69% (38.0 mg); dr &gt;20:1; mp 233.8-234.8 <lb/>°C; 1 H NMR (400 MHz, CDCl 3 ) δ 7.73-7.71 (m, 1H), 7.67-7.60 <lb/>(m, 3H), 7.58-7.51 (m, 3H), 7.51-7.44 (m, 2H), 7.36-7.31 (m, <lb/>4H), 7.28-7.25 (m, 2H), 6.93-6.88 (m, 2H), 6.66 (dd, J = 9.2, 4.4 <lb/>Hz, 1H), 5.02 (s, 2H), 3.57 (d, J = 20.3 Hz, 1H), 3.43 (d, J = 20.3 Hz, <lb/>1H); 13 C{ 1 H} NMR (101 MHz, CDCl 3 ) δ 185.9, 173.1, 168.2, 160.2, <lb/>157.8 (d, J = 244.4 Hz), 147.8, 140.5, 140.3, 139.9, 136.4, 135.9, <lb/>134.4, 134.0, 131.8, 131.4, 129.1, 128.8, 128.6, 128.2, 127.6, 125.4, <lb/>124.9, 121.0 (d, J = 13.1 Hz), 117.6 (d, J = 23.2 Hz), 115.4, 114.4, <lb/>114.1, 111.0 (d, J = 8.1 Hz), 66.1, 61.3, 50.2, 44.6, 36.2; 19 F{ 1 H} <lb/>NMR (376 MHz, CDCl 3 ) δ -117.2; HRMS (ESI) calcd for <lb/>C 35 H 22 N 3 O 3 FNa [M + Na] + 574.1537, found 574.1542. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-benzyl-5-chloro-5′-phe-<lb/>nyl-3′,4′-dihydro-1′H-spiro[indoline-3,11′-[3,10b]-<lb/>methanoindeno[1,2-b]azepine]-2,2′,6′-trione (3c). Following <lb/>the general procedure with 1c (32.0 mg, 0.10 mmol), 2a (37.2 mg, <lb/>0.15 mmol), and quinine (6.8 mg, 20 mol %), the title compound was <lb/>obtained as a brick red powder after purification by column <lb/>chromatography on silica gel using a hexane/ethyl acetate eluent <lb/>(7:1 to 5:1 to 3:1): yield 89% (50.6 mg); dr &gt;20:1; mp 200.0-201.0 <lb/>°C; 1 H NMR (400 MHz, acetone-d 6 ) δ 8.63 (s, 1H), 7.89-7.87 (m, <lb/>2H), 7.65-7.60 (m, 3H), 7.59-7.55 (m, 4H), 7.44-7.42 (m, 2H), <lb/>7.37-7.33 (m, 3H), 7.28-7.24 (m, 2H), 6.96 (d, J = 8.4 Hz, 1H), <lb/>5.27 (d, J = 15.7 Hz, 1H), 5.03 (d, J = 15.7 Hz, 1H), 4.07 (d, J = 20.6 <lb/>Hz, 1H), 3.45 (d, J = 20.6 Hz, 1H); 13 C{ 1 H} NMR (101 MHz, <lb/>acetone-d 6 ) δ 186.6, 173.8, 168.5, 148.8, 143.7, 141.9, 141.2, 137.7, <lb/>136.6, 136.0, 135.7, 132.4, 131.5, 131.4, 129.8, 129.6, 129.2, 128.7, <lb/>128.6, 127.4, 126.3, 124.8, 122.7, 116.9, 112.2, 66.9, 61.4, 50.9, 44.6, <lb/>36.8; HRMS (ESI) calcd for C 35 H 22 N 3 O 3 ClNa [M + Na] + 590.1242, <lb/>found 590.1240. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-benzyl-5-bromo-5′-phe-<lb/>nyl-3′,4′-dihydro-1′H-spiro[indoline-3,11′-[3,10b]-<lb/>methanoindeno[1,2-b]azepine]-2,2′,6′-trione (3d). Following <lb/>the general procedure with 1d (36.4 mg, 0.10 mmol), 2a (37.2 mg, <lb/>0.15 mmol), and quinine (6.8 mg, 20 mol %), the title compound was <lb/>obtained as a brick red powder after purification by column <lb/>chromatography on silica gel using a hexane/ethyl acetate eluent <lb/>(7:1 to 5:1 to 3:1): yield 80% (48.7 mg); dr &gt;20:1; mp 216.9-217.9 <lb/>°C; 1 H NMR (400 MHz, acetone-d 6 ) δ 8.62 (s, 1H), 7.88-7.85 (m, <lb/>2H), 7.64 (dt, J = 7.1, 1.3 Hz, 1H), 7.63-7.60 (m, 2H), 7.60-7.54 <lb/>(m, 4H), 7.45-7.44 (m, 1H), 7.43-7.40 (m, 3H), 7.38-7.32 (m, <lb/>3H), 6.92 (dd, J = 8.1, 0.7 Hz, 1H), 5.26 (d, J = 15.7 Hz, 1H), 5.02 <lb/>(d, J = 15.7 Hz, 1H), 4.05 (d, J = 20.6 Hz, 1H), 3.45 (d, J = 20.6 Hz, <lb/>1H); 13 C{ 1 H} NMR (101 MHz, acetone-d 6 ) δ 186.6, 173.7, 168.5, <lb/>148.8, 144.1, 141.9, 141.2, 137.7, 136.6, 136.0, 135.7, 134.3, 132.4, <lb/>131.5, 130.2, 130.0, 129.8, 129.6, 129.2, 128.74, 128.65, 126.3, 124.8, <lb/>123.0, 116.9, 116.0, 112.7, 66.9, 61.6, 50.9, 44.6, 36.9; HRMS (ESI) <lb/>calcd for C 35 H 22 N 3 O 3 BrNa [M + Na] + 634.0737, found 634.0736. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-benzyl-5-methyl-5′-phe-<lb/>nyl-3′,4′-dihydro-1′H-spiro[indoline-3,11′-[3,10b]-<lb/>methanoindeno[1,2-b]azepine]-2,2′,6′-trione (3e). Following <lb/>the general procedure with 1e (29.9 mg, 0.10 mmol), 2a (37.2 mg, <lb/>0.15 mmol), and quinine (6.8 mg, 20 mol %), the title compound was <lb/>obtained as a red powder after purification by column chromatog-<lb/>raphy on silica gel using a hexane/ethyl acetate eluent (7:1 to 5:1 to <lb/>3:1): yield 86% (46.9 mg); dr &gt;20:1; mp 181.7-182.7 °C; 1 H NMR <lb/>(400 MHz, CDCl 3 ) δ 7.65-7.63 (m, 1H), 7.63-7.60 (m, 2H), 7.59-<lb/>7.57 (m, 1H), 7.54-7.51 (m, 2H), 7.50-7.49 (m, 1H), 7.43-7.36 <lb/>(m, 3H), 7.29-7.21 (m, 5H), 6.95-6.93 (m, 2H), 6.60 (d, J = 8.4 Hz, <lb/>1H), 5.01-4.91 (m, 2H), 3.56 (d, J = 20.2 Hz, 1H), 3.40 (d, J = 20.3 <lb/>Hz, 1H), 2.14 (s, 3H); 13 C{ 1 H} NMR (101 MHz, CDCl 3 ) δ 186.3, <lb/>173.2, 168.6, 147.8, 141.4, 140.7, 140.4, 136.7, 135.8, 134.9, 134.4, <lb/>133.0, 131.5, 131.3, 131.1, 128.9, 128.7, 128.5, 128.0, 127.6, 126.7, <lb/>125.6, 124.7, 119.6, 115.6, 110.1, 66.1, 61.1, 50.2, 44.4, 36.4, 21.4; <lb/>HRMS (ESI) calcd for C 36 H 25 N 3 O 3 Na [M + Na] + 570.1788, found <lb/>570.1778. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-benzyl-5-methoxy-5′-<lb/>phenyl-3′,4′-dihydro-1′H-spiro[indoline-3,11′-[3,10b]-<lb/>methanoindeno[1,2-b]azepine]-2,2′,6′-trione (3f). Following <lb/>the general procedure with 1f (31.5 mg, 0.10 mmol), 2a (37.2 mg, <lb/>0.15 mmol), and quinine (6.8 mg, 20 mol %), the title compound was <lb/>obtained as a yellow orange powder after purification by column <lb/>chromatography on silica gel using a hexane/ethyl acetate eluent (7:1 <lb/>to 5:1 to 3:1): yield 90% (50.6 mg); dr &gt;20:1; mp 200.0-201.0 °C; <lb/>1 H NMR (400 MHz, acetone-d 6 ) δ 8.58 (s, 1H), 7.91-7.89 (m, 2H), <lb/>7.66-7.63 (m, 1H), 7.63-7.58 (m, 2H), 7.58-7.52 (m, 4H), 7.44-<lb/>7.41 (m, 2H), 7.36-7.30 (m, 3H), 6.85-6.74 (m, 3H), 5.21 (d, J = <lb/>15.7 Hz, 1H), 4.97 (d, J = 15.7 Hz, 1H), 4.06 (d, J = 20.4 Hz, 1H), <lb/>3.54 (s, 3H), 3.39 (d, J = 20.4 Hz, 1H); 13 C{ 1 H} NMR (101 MHz, <lb/>acetone-d 6 ) δ 186.8, 173.8, 168.9, 156.6, 148.8, 142.2, 141.2, 137.94, <lb/>137.91, 136.5, 136.4, 135.7, 132.2, 131.6, 130.0, 129.5, 129.1, 128.6, <lb/>128.5, 126.4, 124.7, 121.9, 117.2, 115.8, 114.2, 111.4, 67.0, 61.8, 55.8, <lb/>51.0, 44.5, 36.8; HRMS (ESI) calcd for C 36 H 25 N 3 O 4 Na [M + Na] + <lb/>586.1737, found 586.1743. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-benzyl-6-chloro-5′-phe-<lb/>nyl-3′,4′-dihydro-1′H-spiro[indoline-3,11′-[3,10b]-<lb/>methanoindeno[1,2-b]azepine]-2,2′,6′-trione (3g). Following <lb/>the general procedure with 1g (32.0 mg, 0.10 mmol), 2a (37.2 mg, <lb/>0.15 mmol), and quinine (6.8 mg, 20 mol %), the title compound was <lb/>obtained as a red powder after purification by column chromatog-<lb/>raphy on silica gel using a hexane/ethyl acetate eluent (7:1 to 5:1 to <lb/>3:1): yield 85% (48.1 mg); dr &gt;20:1; mp 184.8-185.8 °C; 1 H NMR <lb/>(400 MHz, CDCl 3 ) δ 7.70 (dt, J = 7.7, 1.0 Hz, 1H), 7.63-7.61 (m, <lb/>2H), 7.57-7.50 (m, 4H), 7.47 (dd, J = 7.4, 1.3 Hz, 1H), 7.43 (dd, J = <lb/>7.5, 1.4 Hz, 1H), 7.35-7.32 (m, 3H), 7.29-7.26 (m, 2H), 7.04-7.02 <lb/>(m, 2H), 6.87 (dd, J = 8.3, 1.9 Hz, 1H), 6.73 (d, J = 1.9 Hz, 1H), <lb/>5.03-4.94 (m, 2H), 3.57 (d, J = 20.3 Hz, 1H), 3.40 (d, J = 20.2 Hz, <lb/>1H); 13 C{ 1 H} NMR (101 MHz, CDCl 3 ) δ 185.9, 173.3, 168.1, 148.1, <lb/>145.2, 140.5, 140.3, 137.3, 136.0, 134.2, 133.9, 131.9, 131.5, 129.2, <lb/>128.8, 128.7, 128.4, 127.7, 126.7, 125.3, 125.0, 123.6, 117.9, 115.3, <lb/>111.0, 66.0, 61.0, 50.1, 44.6, 36.2; HRMS (ESI) calcd for <lb/>C 35 H 22 N 3 O 3 ClNa [M + Na] + 590.1242, found 590.1238. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-benzyl-6-bromo-5′-phe-<lb/>nyl-3′,4′-dihydro-1′H-spiro[indoline-3,11′-[3,10b]-<lb/>methanoindeno[1,2-b]azepine]-2,2′,6′-trione (3h). Following <lb/>the general procedure with 1h (36.4 mg, 0.10 mmol), 2a (37.2 mg, <lb/>0.15 mmol), and quinine (6.8 mg, 20 mol %), the title compound was <lb/>obtained as a brick red powder after purification by column <lb/></body>

			<note place="headnote">The Journal of Organic Chemistry <lb/> pubs.acs.org/joc <lb/>Note <lb/></note>

			<note place="footnote">https://doi.org/10.1021/acs.joc.5c00443 <lb/>J. Org. Chem. XXXX, XXX, XXX-XXX <lb/></note>

			<page>E <lb/></page>

			<body>chromatography on silica gel using a hexane/ethyl acetate eluent (7:1 <lb/>to 5:1 to 3:1): yield 80% (49.0 mg); dr &gt;20:1; mp 222.8-223.8 °C; <lb/>1 <lb/>H NMR (400 MHz, CDCl 3 ) δ 7.66 (d, J = 7.5 Hz, 1H), 7.61 (d, J = <lb/>7.3 Hz, 2H), 7.56-7.37 (m, 7H), 7.32-7.30 (m, 3H), 7.25-7.22 (m, <lb/>2H), 7.01 (d, J = 8.3 Hz, 1H), 6.95 (d, J = 8.2 Hz, 1H), 6.85 (s, 1H), <lb/>4.98-4.90 (m, 2H), 3.54 (d, J = 20.3 Hz, 1H), 3.36 (d, J = 20.1 Hz, <lb/>1H); 13 C{ 1 H} NMR (101 MHz, CDCl 3 ) δ 186.0, 173.2, 168.3, 147.9, <lb/>145.1, 140.4, 140.3, 136.5, 135.9, 134.2, 133.9, 131.8, 131.4, 129.1, <lb/>128.8, 128.7, 128.3, 127.6, 126.9, 126.5, 125.4, 125.2, 124.9, 118.5, <lb/>115.4, 113.7, 66.0, 61.1, 50.1, 44.5, 36.1; HRMS (ESI) m/z calcd for <lb/>C 35 H 21 O 3 N 3 Br [M -H] -610.0761, found 610.0777. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-benzyl-6-methoxy-5′-<lb/>phenyl-3′,4′-dihydro-1′H-spiro[indoline-3,11′-[3,10b]-<lb/>methanoindeno[1,2-b]azepine]-2,2′,6′-trione (3i). Following <lb/>the general procedure with 1i (31.5 mg, 0.10 mmol), 2a (37.2 mg, <lb/>0.15 mmol), and quinine (6.8 mg, 20 mol %), the title compound was <lb/>obtained as a brick red powder after purification by column <lb/>chromatography on silica gel using a hexane/ethyl acetate eluent <lb/>(7:1 to 5:1 to 3:1): yield 87% (48.7 mg); dr &gt;20:1; mp 244.3-245.3 <lb/>°C; 1 H NMR (400 MHz, CDCl 3 ) δ 7.65-7.62 (m, 3H), 7.59-7.56 <lb/>(m, 1H), 7.53-7.47 (m, 2H), 7.44-7.36 (m, 3H), 7.29-7.23 (m, <lb/>5H), 7.00 (d, J = 8.6 Hz, 1H), 6.33 (dd, J = 8.7, 2.4 Hz, 1H), 6.25 (d, <lb/>J = 2.4 Hz, 1H), 4.98-4.89 (m, 2H), 3.60 (s, 3H), 3.57 (d, J = 20.3 <lb/>Hz, 1H), 3.34 (d, J = 20.1 Hz, 1H); 13 C{ 1 H} NMR (101 MHz, <lb/>CDCl 3 ) δ 186.3, 173.8, 168.6, 161.8, 147.9, 145.2, 140.7, 140.5, 136.8, <lb/>135.8, 134.8, 134.2, 131.5, 131.2, 129.0, 128.8, 128.6, 128.1, 127.6, <lb/>126.7, 125.5, 124.7, 115.7, 111.1, 107.1, 98.4, 66.1, 61.1, 55.5, 50.3, <lb/>44.4, 36.3; HRMS (ESI) m/z calcd for C 36 H 24 O 4 N 3 [M -H] -<lb/>562.1761, found 562.1761. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-benzyl-7-fluoro-5′-phe-<lb/>nyl-3′,4′-dihydro-1′H-spiro[indoline-3,11′-[3,10b]-<lb/>methanoindeno[1,2-b]azepine]-2,2′,6′-trione (3j). Following <lb/>the general procedure with 1j (30.3 mg, 0.10 mmol), 2a (37.2 mg, <lb/>0.15 mmol), and quinine (6.8 mg, 20 mol %), the title compound was <lb/>obtained as a brick red powder after purification by column <lb/>chromatography on silica gel using a hexane/ethyl acetate eluent <lb/>(7:1 to 5:1 to 3:1): yield 54% (29.8 mg); dr 17:1; mp 199.0-200.0 <lb/>°C; 1 H NMR (400 MHz, CDCl 3 ) δ 7.64-7.61 (m, 3H), 7.54-7.47 <lb/>(m, 4H), 7.43-7.38 (m, 3H), 7.35-7.25 (m, 5H), 6.99-6.91 (m, <lb/>2H), 6.86-6.82 (m, 1H), 5.19 (d, J = 15.1 Hz, 1H), 5.07 (d, J = 15.1 <lb/>Hz, 1H), 3.57 (d, J = 20.2 Hz, 1H), 3.37 (d, J = 20.2 Hz, 1H); <lb/>13 <lb/>C{ 1 H} NMR (101 MHz, CDCl 3 ) δ 186.0, 173.1, 168.32, 168.28, <lb/>147.9, 147.7 (d, J = 245.8 Hz), 140.3, 140.1, 136.5, 135.9, 134.0, <lb/>131.6, 131.4, 128.80, 128.77, 128.7, 128.10, 128.06, 125.4, 125.3, <lb/>124.7, 124.2 (d, J = 6.8 Hz), 122.5, 121.7 (d, J = 2.8 Hz), 119.4 (d, J = <lb/>19.6 Hz), 115.4, 66.3, 61.1, 50.3, 46.2, 36.1; 19 F{ 1 H} NMR (376 <lb/>MHz, CDCl 3 ) δ -130.8; HRMS (ESI) m/z calcd for C 35 H 21 O 3 N 3 F <lb/>[M -H] -550.1561, found 550.1574. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-benzyl-5′-(4-fluoro-<lb/>phenyl)-3′,4′-dihydro-1′H-spiro[indoline-3,11′-[3,10b]-<lb/>methanoindeno[1,2-b]azepine]-2,2′,6′-trione (3k). Following <lb/>the general procedure with 1a (28.5 mg, 0.10 mmol), 2b (39.9 mg, <lb/>0.15 mmol), and quinine (6.8 mg, 20 mol %), the title compound was <lb/>obtained as a brick red powder after purification by column <lb/>chromatography on silica gel using a hexane/ethyl acetate eluent <lb/>(7:1 to 5:1 to 3:1): yield 87% (48.1 mg); dr &gt;20:1; mp 175.0-176.0 <lb/>°C; 1 H NMR (400 MHz, CDCl 3 ) δ 7.66-7.63 (m, 3H), 7.59 (dd, <lb/>1H), 7.56-7.49 (m, 4H), 7.44-7.37 (m, 2H), 7.32-7.23 (m, 4H), <lb/>7.17-7.10 (m, 2H), 6.87 (t, J = 7.7 Hz, 1H), 6.71 (d, J = 7.8 Hz, 1H), <lb/>5.03-4.95 (m, 2H), 3.60 (d, J = 20.1 Hz, 1H), 3.38 (d, J = 20.2 Hz, <lb/>1H); 13 C{ 1 H} NMR (101 MHz, CDCl 3 ) δ 186.2, 173.3, 168.4, 164.5 <lb/>(d, J = 254.5 Hz), 146.8, 143.9, 140.6, 140.4, 136.8, 135.9, 134.7, <lb/>131.7, 131.14, 131.07 (d, J = 30.3 Hz), 130.1 (d, J = 30.3 Hz), 129.1, <lb/>129.0, 128.1, 127.8, 127.7, 125.6, 125.5, 125.4, 124.8, 123.6, 119.5, <lb/>115.9 (d, J = 22.2 Hz), 115.5, 110.4, 66.2, 61.3, 50.3, 44.5, 36.3; <lb/>19 <lb/>F{ 1 H} NMR (376 MHz, CDCl 3 ) δ -107.7; HRMS (ESI) calcd for <lb/>C 35 H 22 N 3 O 3 FNa [M + Na] + 574.1537, found 574.1534. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-benzyl-5′-(4-chloro-<lb/>phenyl)-3′,4′-dihydro-1′H-spiro[indoline-3,11′-[3,10b]-<lb/>methanoindeno[1,2-b]azepine]-2,2′,6′-trione (3l). Following <lb/>the general procedure with 1a (28.5 mg, 0.10 mmol), 2c (42.3 mg, <lb/>0.15 mmol), and quinine (6.8 mg, 20 mol %), the title compound was <lb/>obtained as a brick red powder after purification by column <lb/>chromatography on silica gel using a hexane/ethyl acetate eluent <lb/>(7:1 to 5:1 to 3:1): yield 77% (43.9 mg); dr &gt;20:1; mp 223.1-224.1 <lb/>°C; 1 H NMR (400 MHz, CDCl 3 ) δ 7.66-7.56 (m, 5H), 7.49-7.44 <lb/>(m, 2H), 7.43-7.37 (m, 2H), 7.33-7.23 (m, 5H), 7.16 (t, J = 7.8 Hz, <lb/>1H), 7.04 (d, J = 7.8 Hz, 1H), 6.86 (t, J = 7.7 Hz, 1H), 6.71 (d, J = 8.0 <lb/>Hz, 1H), 5.02-4.93 (m, 2H), 3.56 (d, J = 20.1 Hz, 1H), 3.35 (d, J = <lb/>20.1 Hz, 1H); 13 C{ 1 H} NMR (101 MHz, CDCl 3 ) δ 186.2, 173.2, <lb/>168.6, 146.5, 143.8, 140.5, 140.3, 137.4, 137.1, 136.0, 134.6, 132.4, <lb/>131.6, 131.1, 130.3, 129.0, 128.9, 128.1, 127.6, 125.6, 125.5, 124.8, <lb/>123.6, 119.4, 115.5, 110.4, 66.1, 61.2, 50.2, 44.4, 35.9; HRMS (ESI) <lb/>calcd for C 35 H 22 N 3 O 3 ClNa [M + Na] + 590.1242, found 590.1245. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-benzyl-5′-(4-bromo-<lb/>phenyl)-3′,4′-dihydro-1′H-spiro[indoline-3,11′-[3,10b]-<lb/>methanoindeno[1,2-b]azepine]-2,2′,6′-trione (3m). Following <lb/>the general procedure with 1a (28.5 mg, 0.10 mmol), 2d (49.1 mg, <lb/>0.15 mmol), and quinine (6.8 mg, 20 mol %), the title compound was <lb/>obtained as a brick red powder after purification by column <lb/>chromatography on silica gel using a hexane/ethyl acetate eluent <lb/>(7:1 to 5:1 to 3:1): yield 91% (55.7 mg); dr &gt;20:1; mp 181.7-182.7 <lb/>°C; 1 H NMR (400 MHz, CDCl 3 ) δ 7.68-7.65 (m, 3H), 7.59-7.53 <lb/>(m, 3H), 7.47-7.38 (m, 3H), 7.34-7.24 (m, 5H), 7.18 (t, J = 7.7 Hz, <lb/>1H), 7.04 (d, J = 7.7 Hz, 1H), 6.88 (t, J = 7.7 Hz, 1H), 6.73 (d, J = 7.9 <lb/>Hz, 1H), 5.04-4.95 (m, 2H), 3.58 (d, J = 20.2 Hz, 1H), 3.37 (d, J = <lb/>20.1 Hz, 1H); 13 C{ 1 H} NMR (101 MHz, CDCl 3 ) δ 186.2, 173.2, <lb/>168.5, 146.6, 143.9, 140.5, 140.3, 137.1, 136.0, 134.7, 132.9, 131.9, <lb/>131.7, 131.1, 130.4, 129.0, 128.1, 127.6, 125.9, 125.6, 125.4, 124.8, <lb/>123.6, 119.4, 115.5, 110.5, 66.1, 61.1, 50.2, 44.4, 35.9; HRMS (ESI) <lb/>calcd for C 35 H 22 N 3 O 3 BrNa [M + Na] + 634.0737, found 634.0743. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-benzyl-5′-(4-methyl-<lb/>phenyl)-3′,4′-dihydro-1′H-spiro[indoline-3,11′-[3,10b]-<lb/>methanoindeno[1,2-b]azepine]-2,2′,6′-trione (3n). Following <lb/>the general procedure with 1a (28.5 mg, 0.10 mmol), 2e (39.3 mg, <lb/>0.15 mmol), and quinine (6.8 mg, 20 mol %), the title compound was <lb/>obtained as a brick red powder after purification by column <lb/>chromatography on silica gel using a hexane/ethyl acetate eluent <lb/>(7:1 to 5:1 to 3:1): yield 88% (47.9 mg); dr &gt;20:1; mp 185.8-186.8 <lb/>°C; 1 H NMR (400 MHz, CDCl 3 ) δ 7.64-7.61 (m, 1H), 7.57-7.53 <lb/>(m, 3H), 7.42-7.34 (m, 3H), 7.33-7.22 (m, 7H), 7.12 (t, J = 7.7 Hz, <lb/>1H), 7.07 (d, J = 7.7 Hz, 1H), 6.82 (t, J = 7.7 Hz, 1H), 6.68 (d, J = 7.8 <lb/>Hz, 1H), 5.02-4.93 (m, 2H), 3.58 (d, J = 20.1 Hz, 1H), 3.34 (d, J = <lb/>20.1 Hz, 1H), 2.46 (s, 3H); 13 C{ 1 H} NMR (101 MHz, CDCl 3 ) δ <lb/>186.2, 173.3, 168.6, 148.2, 143.8, 142.0, 140.5, 136.1, 135.7, 134.8, <lb/>131.5, 131.3, 130.9, 129.3, 129.0, 128.8, 128.1, 127.6, 125.8, 125.4, <lb/>124.7, 123.6, 119.6, 115.7, 110.3, 66.2, 61.3, 50.2, 44.4, 36.1, 21.7; <lb/>HRMS (ESI) calcd for C 36 H 25 N 3 O 3 Na [M + Na] + 570.1788, found <lb/>570.1790. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-benzyl-5′-(4-methoxy-<lb/>phenyl)-3′,4′-dihydro-1′H-spiro[indoline-3,11′-[3,10b]-<lb/>methanoindeno[1,2-b]azepine]-2,2′,6′-trione (3o). Following <lb/>the general procedure with 1a (28.5 mg, 0.10 mmol), 2f (41.7 mg, <lb/>0.15 mmol), and quinine (6.8 mg, 20 mol %), the title compound was <lb/>obtained as a yellow powder after purification by column <lb/>chromatography on silica gel using a hexane/ethyl acetate eluent <lb/>(7:1 to 5:1 to 3:1): yield 68% (38.2 mg); dr &gt;20:1; mp 233.5-234.5 <lb/>°C; 1 H NMR (400 MHz, CDCl 3 ) δ 7.68-7.64 (m, 3H), 7.59 (d, J = <lb/>8.0 Hz, 1H), 7.45-7.35 (m, 3H), 7.30-7.23 (m, 5H), 7.14 (td, J = <lb/>7.8, 1.2 Hz, 1H), 7.06-7.02 (m, 3H), 6.84 (td, J = 7.8, 1.1 Hz, 1H), <lb/>6.69 (dd, J = 8.0, 1.1 Hz, 1H), 5.04-4.95 (m, 2H), 3.90 (s, 3H), 3.64 <lb/>(d, J = 19.9 Hz, 1H), 3.35 (d, J = 19.9 Hz, 1H); 13 C{ 1 H} NMR (101 <lb/>MHz, CDCl 3 ) δ 186.2, 173.3, 168.6, 162.4, 148.1, 143.8, 140.6, 140.5, <lb/>135.6, 135.2, 134.8, 131.5, 130.92, 130.85, 129.0, 128.1, 127.6, 126.3, <lb/>125.8, 125.3, 124.7, 123.6, 119.6, 115.7, 114.0, 110.3, 61.4, 55.6, 50.2, <lb/>44.4, 36.0; HRMS (ESI) calcd for C 36 H 25 N 3 O 4 Na [M + Na] + <lb/>586.1738, found 586.1741. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-benzyl-5′-(naphthalen-<lb/>2-yl)-3′,4′-dihydro-1′H-spiro[indoline-3,11′-[3,10b]-<lb/>methanoindeno[1,2-b]azepine]-2,2′,6′-trione (3p). Following <lb/>the general procedure with 1a (28.5 mg, 0.10 mmol), 2g (44.7 mg, <lb/></body>

			<note place="headnote">The Journal of Organic Chemistry <lb/> pubs.acs.org/joc <lb/>Note <lb/></note>

			<note place="footnote">https://doi.org/10.1021/acs.joc.5c00443 <lb/>J. Org. Chem. XXXX, XXX, XXX-XXX <lb/></note>

			<page>F <lb/></page>

			<body>0.15 mmol), and quinine (6.8 mg, 20 mol %), the title compound was <lb/>obtained as a brick red powder after purification by column <lb/>chromatography on silica gel using a hexane/ethyl acetate eluent <lb/>(7:1 to 5:1 to 3:1): yield 82% (47.7 mg); dr &gt;20:1; mp 220.4-221.4 <lb/>°C; 1 H NMR (400 MHz, CDCl 3 ) δ 8.11 (d, J = 1.8 Hz, 1H), 7.93-<lb/>7.86 (m, 3H), 7.74 (dd, J = 8.5, 1.9 Hz, 1H), 7.65-7.62 (m, 1H), <lb/>7.59-7.51 (m, 3H), 7.46-7.45 (m, 1H), 7.42-7.35 (m, 2H), 7.30-<lb/>7.21 (m, 5H), 7.17-7.11 (m, 2H), 6.89 (td, J = 7.8, 1.1 Hz, 1H), 6.72 <lb/>(d, J = 7.8 Hz, 1H), 5.01-4.91 (m, 2H), 3.75 (d, J = 20.1 Hz, 1H), <lb/>3.45 (d, J = 20.1 Hz, 1H); 13 C{ 1 H} NMR (101 MHz, CDCl 3 ) δ <lb/>186.2, 173.3, 168.7, 148.0, 143.9, 140.6, 140.5, 136.9, 135.8, 134.7, <lb/>134.7, 132.9, 131.8, 131.6, 131.0, 129.1, 129.0, 128.5, 128.09, 128.07, <lb/>127.94, 127.89, 127.6, 126.9, 126.5, 125.8, 125.5, 124.8, 123.7, 119.6, <lb/>115.7, 110.4, 66.3, 61.3, 50.3, 44.4, 36.3; HRMS (ESI) calcd for <lb/>C 39 H 25 N 3 O 3 Na [M + Na] + 606.1788, found 606.1783. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-benzyl-5′-(thiophen-2-<lb/>yl)-3′,4′-dihydro-1′H-spiro[indoline-3,11′-[3,10b]-<lb/>methanoindeno[1,2-b]azepine]-2,2′,6′-trione (3q). Following <lb/>the general procedure with 1a (28.5 mg, 0.10 mmol), 2h (38.1 mg, <lb/>0.15 mmol), and quinine (6.8 mg, 20 mol %), the title compound was <lb/>obtained as a brick red powder after purification by column <lb/>chromatography on silica gel using a hexane/ethyl acetate eluent <lb/>(7:1 to 5:1 to 3:1): yield 74% (39.7 mg); dr &gt;20:1; mp 257.9-258.9 <lb/>°C; 1 H NMR (400 MHz, acetone-d 6 ) δ 8.51 (s, 1H), 8.35 (dd, J = <lb/>3.9, 1.2 Hz, 1H), 7.90 (dd, J = 5.0, 1.1 Hz, 1H), 7.65 (dd, J = 6.5, 1.7 <lb/>Hz, 1H), 7.61-7.50 (m, 3H), 7.42-7.39 (m, 2H), 7.34-7.28 (m, <lb/>4H), 7.17 (td, J = 7.8, 1.3 Hz, 1H), 7.01 (d, J = 7.8 Hz, 1H), 6.89 (d, J <lb/>= 7.9 Hz, 1H), 6.84 (td, J = 7.7, 1.1 Hz, 1H), 5.21 (d, J = 15.6 Hz, <lb/>1H), 4.98 (d, J = 15.6 Hz, 1H), 3.92 (d, J = 19.7 Hz, 1H), 3.74 (d, J = <lb/>19.7 Hz, 1H); 13 C{ 1 H} NMR (101 MHz, acetone-d 6 ) δ 186.2, 173.2, <lb/>168.2, 144.0, 141.2, 140.3, 139.3, 136.9, 135.6, 135.5, 134.2, 133.2, <lb/>132.1, 131.4, 130.7, 128.8, 127.82, 127.80, 127.7, 125.9, 125.3, 123.8, <lb/>123.1, 120.0, 116.2, 110.2, 66.7, 61.0, 50.1, 43.7, 36.0; HRMS (ESI) <lb/>m/z calcd for C 33 H 20 O 3 N 3 S [M -H] -538.1220, found 538.1238. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-(4-methoxybenzyl)-5′-<lb/>phenyl-3′,4′-dihydro-1′H-spiro[indoline-3,11′-[3,10b]-<lb/>methanoindeno[1,2-b]azepine]-2,2′,6′-trione (3r). Following <lb/>the general procedure with 1k (31.5 mg, 0.10 mmol), 2a (37.2 mg, <lb/>0.15 mmol), and quinine (6.8 mg, 20 mol %), the title compound was <lb/>obtained as a brick red powder after purification by column <lb/>chromatography on silica gel using a hexane/ethyl acetate eluent <lb/>(7:1 to 5:1 to 3:1): yield 84% (47.3 mg); dr &gt;20:1; mp 194.5-195.5 <lb/>°C; 1 H NMR (400 MHz, CDCl 3 ) δ 7.66-7.62 (m, 3H), 7.59-7.56 <lb/>(m, 1H), 7.55-7.49 (m, 3H), 7.45-7.389 (m, 2H), 7.25-7.19 (m, <lb/>3H), 7.16 (td, J = 7.7, 1.2 Hz, 1H), 7.10 (dd, J = 7.8, 1.2 Hz, 1H), <lb/>6.88-6.80 (m, 3H), 6.73 (dd, J = 7.8, 1.1 Hz, 1H), 4.97 (d, J = 15.4 <lb/>Hz, 1H), 4.89 (d, J = 15.3 Hz, 1H), 3.77 (s, 3H), 3.59 (d, J = 20.3 Hz, <lb/>1H), 3.38 (d, J = 20.1 Hz, 1H); 13 C{ 1 H} NMR (101 MHz, CDCl 3 ) δ <lb/>186.2, 173.2, 168.5, 159.4, 148.0, 143.9, 140.6, 140.4, 136.7, 135.8, <lb/>134.2, 131.6, 131.3, 130.9, 129.1, 128.8, 128.7, 126.8, 125.7, 125.4, <lb/>124.7, 123.5, 119.6, 115.6, 114.3, 110.3, 66.1, 61.1, 55.4, 50.2, 43.9, <lb/>36.3; HRMS (ESI) m/z calcd for C 36 H 24 O 4 N 3 [M -H] -562.1761, <lb/>found 562.1762. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-(4-bromobenzyl)-5′-<lb/>phenyl-3′,4′-dihydro-1′H-spiro[indoline-3,11′-[3,10b]-<lb/>methanoindeno[1,2-b]azepine]-2,2′,6′-trione (3s). Following <lb/>the general procedure with 1l (36.4 mg, 0.10 mmol), 2a (37.2 mg, <lb/>0.15 mmol), and quinine (6.8 mg, 20 mol %), the title compound was <lb/>obtained as a brick red powder after purification by column <lb/>chromatography on silica gel using a hexane/ethyl acetate eluent <lb/>(7:1 to 5:1 to 3:1): yield 36% (22.2 mg); dr &gt;20:1; mp 245.0-246.0 <lb/>°C; 1 H NMR (400 MHz, CDCl 3 ) δ 7.68-7.62 (m, 3H), 7.56-7.41 <lb/>(m, 8H), 7.20-7.11 (m, 4H), 7.03 (bs, 1H), 6.89 (t, J = 7.5 Hz, 1H), <lb/>6.68 (d, J = 7.9 Hz, 1H), 5.00 (d, J = 15.7 Hz, 1H), 4.91 (d, J = 15.8 <lb/>Hz, 1H), 3.60 (d, J = 20.1 Hz, 1H), 3.39 (d, J = 20.2 Hz, 1H); <lb/>13 <lb/>C{ 1 H} NMR (101 MHz, CDCl 3 ) δ 186.0, 173.3, 168.3, 148.1, <lb/>143.5, 140.5, 136.5, 135.8, 134.1, 133.8, 132.1, 131.7, 131.4, 131.1, <lb/>129.4, 128.7, 128.7, 125.9, 125.2, 124.9, 123.8, 122.1, 119.5, 115.5, <lb/>110.2, 66.1, 61.1, 50.2, 43.8, 36.3; HRMS (ESI) m/z calcd for <lb/>C 35 H 21 O 3 N 3 Br [M -H] -610.0761, found 610.0766. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-methyl-5′-phenyl-3′,4′-<lb/>dihydro-1′H-spiro[indoline-3,11′-[3,10b]methanoindeno[1,2-<lb/>b]azepine]-2,2′,6′-trione (3t). Following the general procedure <lb/>with 1m (20.9 mg, 0.10 mmol), 2a (37.2 mg, 0.15 mmol), and <lb/>quinine (6.8 mg, 20 mol %), the title compound was obtained as a red <lb/>powder after purification by column chromatography on silica gel <lb/>using a hexane/ethyl acetate eluent (7:1 to 5:1 to 3:1): yield 98% <lb/>(44.8 mg); dr &gt;20:1; mp 177.7-178.7 °C; 1 H NMR (400 MHz, <lb/>CDCl 3 ) δ 7.76-7.65 (m, 5H), 7.61-7.50 (m, 4H), 7.32-7.26 (m, <lb/>2H), 7.11 (d, J = 7.6 Hz, 1H), 6.91 (t, J = 7.7 Hz, 1H), 6.79 (d, J = 7.7 <lb/>Hz, 1H), 3.59 (d, J = 20.3 Hz, 1H), 3.43-3.33 (m, 4H); 13 C{ 1 H} <lb/>NMR (101 MHz, CDCl 3 ) δ 186.2, 173.1, 168.5, 148.0, 144.6, 140.7, <lb/>140.5, 136.6, 135.9, 134.2, 131.6, 131.3, 131.0, 128.8, 128.7, 125.6, <lb/>125.0, 124.8, 123.6, 119.5, 115.5, 109.4, 66.1, 61.3, 50.0, 36.3, 26.9; <lb/>HRMS (ESI) calcd for C 29 H 19 N 3 O 3 Na [M + Na] + 480.1319, found <lb/>480.1310. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-ethyl-5′-phenyl-3′,4′-di-<lb/>hydro-1′H-spiro[indoline-3,11′-[3,10b]methanoindeno[1,2-b]-<lb/>azepine]-2,2′,6′-trione (3u). Following the general procedure with <lb/>1n (22.3 mg, 0.10 mmol), 2a (37.2 mg, 0.15 mmol), and quinine (6.8 <lb/>mg, 20 mol %), the title compound was obtained as a brick red <lb/>powder after purification by column chromatography on silica gel <lb/>using a hexane/ethyl acetate eluent (7:1 to 5:1 to 3:1): yield 88% <lb/>(41.3 mg); dr &gt;20:1; mp 218.7-219.7 °C; 1 H NMR (400 MHz, <lb/>CDCl 3 ) δ 7.74 (dd, J = 7.7, 2.9 Hz, 1H), 7.67-7.63 (m, 3H), 7.61-<lb/>7.56 (m, 1H), 7.54-7.49 (m, 3H), 7.47-7.37 (m, 2H), 7.24 (t, J = <lb/>7.9 Hz, 1H), 7.10 (d, J = 7.7 Hz, 1H), 6.88 (t, J = 7.7 Hz, 1H), 6.79 <lb/>(d, J = 7.8 Hz, 1H), 3.83 (q, J = 7.0 Hz, 2H), 3.56 (d, J = 20.1 Hz, <lb/>1H), 3.34 (d, J = 20.2 Hz, 1H), 1.26 (t, J = 7.0 Hz, 3H); 13 C{ 1 H} <lb/>NMR (101 MHz, CDCl 3 ) δ 186.3, 172.7, 168.6, 147.9, 143.6, 140.8, <lb/>140.5, 136.7, 135.8, 134.2, 131.6, 131.2, 131.0, 128.8, 128.6, 125.8, <lb/>125.3, 124.7, 123.3, 119.8, 115.4, 109.5, 66.0, 60.9, 50.1, 36.2, 35.4, <lb/>12.5; HRMS (ESI) m/z calcd for C 30 H 20 O 3 N 3 [M -H] -470.1499, <lb/>found 470.1502. <lb/>3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-allyl-5′-phenyl-3′,4′-di-<lb/>hydro-1′H-spiro[indoline-3,11′-[3,10b]methanoindeno[1,2-b]-<lb/>azepine]-2,2′,6′-trione (3v). Following the general procedure with <lb/>1o (23.5 mg, 0.10 mmol), 2a (37.2 mg, 0.15 mmol), and quinine (6.8 <lb/>mg, 20 mol %), the title compound was obtained as a brick red <lb/>powder after purification by column chromatography on silica gel <lb/>using a hexane/ethyl acetate eluent (7:1 to 5:1 to 3:1): yield 77% <lb/>(37.1 mg); dr &gt;20:1; mp 187.3-188.3 °C; 1 H NMR (400 MHz, <lb/>CDCl 3 ) δ 7.74-7.46 (m, 9H), 7.22 (dd, J = 7.8, 1.2 Hz, 1H), 7.11 <lb/>(dd, J = 7.9, 1.2 Hz, 1H), 6.89 (td, J = 7.7, 1.1 Hz, 1H), 6.84 (d, J = <lb/>5.3 Hz, 1H), 6.77 (d, J = 7.9 Hz, 1H), 5.83-5.76 (m, 1H), 5.23-5.13 <lb/>(m, 2H), 4.57-4.51 (m, 1H), 4.40-4.35 (m, 1H), 3.61 (d, J = 20.2 <lb/>Hz, 1H), 3.38 (d, J = 20.2 Hz, 1H); 13 C{ 1 H} NMR (101 MHz, <lb/>CDCl 3 ) δ 186.1, 172.8, 168.2, 148.1, 143.9, 140.6, 140.5, 136.6, 135.8, <lb/>134.1, 131.7, 131.3, 131.0, 130.4, 128.7, 128.7, 125.7, 125.4, 124.8, <lb/>123.5, 119.4, 118.5, 115.4, 110.3, 66.0, 61.1, 50.1, 42.8, 36.4; HRMS <lb/>(ESI) m/z calcd for C 31 H 20 O 3 N 3 [M -H] -482.1499, found <lb/>482.1502. <lb/>tert-Butyl 3′-((λ 2 -Azaneylidene)-λ 3 -methyl)-1-benzyl-6-<lb/>bromo-6′-((tert-butoxycarbonyl)oxy)-2,2′-dioxo-5′-phenyl-<lb/>2 ′ , 3 ′ -d i h y d r o -1 ′ H -s p i r o [ i n d o l i n e -3 , 1 1 ′ -[ 3 , 1 0 b ] -<lb/>methanoindeno[1,2-b]azepine]-1′-carboxylate (4). In a 7 mL <lb/>glass vial, compound 3h (61.2 mg, 0.1 mmol) was dissolved in <lb/>dichloromethane (1.0 mL) with triethylamine (14 μL, 0.1 mmol) and <lb/>DMAP (1.2 mg, 0.01 mmol). Consequently, Boc 2 O (65.5 mg, 0.3 <lb/>mmol) was added to the mixture, and it was stirred at room <lb/>temperature overnight. After completion of the reaction (determined <lb/>by TLC), the reaction mixture was extracted with saturated NH 4 Cl (aq) <lb/>(2 × 10 mL). Then, the combined organic layer was washed with <lb/>brine (2 × 20 mL) and dried over anhydrous Na 2 SO 4 , and the crude <lb/>product was purified by silica gel column chromatography using a 5:1 <lb/>hexane/ethyl acetate eluent to obtain product 4 (61.3 mg, 75% yield) <lb/>as a yellow powder: dr &gt;20:1; mp 203.0-204.0 °C; 1 H NMR (400 <lb/>MHz, CDCl 3 ) δ 7.46-7.41 (m, 5H), 7.33-7.28 (m, 5H), 7.21 (dd, J <lb/>= 6.7, 2.8 Hz, 2H), 7.18 (d, J = 8.3 Hz, 1H), 7.15 (d, J = 7.6 Hz, 1H), <lb/>7.08 (td, J = 7.6, 1.1 Hz, 1H), 7.00 (dd, J = 8.3, 1.8 Hz, 1H), 6.72 (d, J <lb/>= 1.8 Hz, 1H), 6.15 (s, 1H), 4.99 (d, J = 15.7 Hz, 1H), 4.91 (d, J = <lb/></body>

			<note place="headnote">The Journal of Organic Chemistry <lb/> pubs.acs.org/joc <lb/>Note <lb/></note>

			<note place="footnote">https://doi.org/10.1021/acs.joc.5c00443 <lb/>J. Org. Chem. XXXX, XXX, XXX-XXX <lb/></note>

			<page>G <lb/></page>

			<body>15.7 Hz, 1H), 1.28 (s, 9H), 1.08 (s, 9H); 13 C{ 1 H} NMR (101 MHz, <lb/>CDCl 3 ) δ 172.6, 163.6, 148.7, 148.1, 147.2, 144.6, 139.2, 139.0, 138.4, <lb/>135.8, 134.3, 130.0, 129.5, 129.0, 128.7, 128.5, 128.2, 127.6, 127.5, <lb/>126.3, 124.9, 123.1, 122.1, 120.9, 119.7, 117.6, 114.4, 112.7, 84.8, <lb/>84.1, 72.5, 60.8, 54.7, 44.4, 27.5, 27.4; HRMS (ESI) m/z calcd for <lb/>C 45 H 37 ON 3 Br [M -H] -810.1809, found 810.1827. <lb/></body>
				
			<div type="availability">■ ASSOCIATED CONTENT <lb/> Data Availability Statement <lb/>The data underlying this study are available in the published <lb/>article and its Supporting Information. <lb/></div>

			<div type="annex">* sı Supporting Information <lb/>The Supporting Information is available free of charge at <lb/>https://pubs.acs.org/doi/10.1021/acs.joc.5c00443. <lb/>General information, X-ray analysis data, and NMR <lb/>spectra of all compounds (PDF) <lb/>Accession Codes <lb/>Deposition Number 2370395 contains the supplementary <lb/>crystallographic data for this paper. These data can be obtained <lb/>free of charge via the joint Cambridge Crystallographic Data <lb/>Centre (CCDC) and Fachinformationszentrum Karlsruhe <lb/>Access Structures service. <lb/></div>

			<front>■ AUTHOR INFORMATION <lb/>Corresponding Author <lb/>Jeng-Liang Han -Department of Chemistry, National Chung <lb/>Hsing University, Taichung 40227, Taiwan; orcid.org/ <lb/>0000-0002-7239-6548; Email: jlhan@nchu.edu.tw <lb/>Authors <lb/>I-Ting Chen -Department of Chemistry, National Chung <lb/>Hsing University, Taichung 40227, Taiwan <lb/>Hsuan Lin -Department of Chemistry, National Chung Hsing <lb/>University, Taichung 40227, Taiwan <lb/>Complete contact information is available at: <lb/>https://pubs.acs.org/10.1021/acs.joc.5c00443 <lb/></front>

			<div type="annex">Notes <lb/>The authors declare no competing financial interest. <lb/></div>

			<div type="acknowledgement">■ ACKNOWLEDGMENTS <lb/>The authors are grateful for the financial support from the <lb/>National Science and Technology Council, Taiwan (113-2113-<lb/>M-005-004). The authors thank the mass center of institute of <lb/>chemistry, Academia Sinica, for HRMS measurement. The <lb/>support of X-ray measurements by the Instrument Center of <lb/>National Chung Hsing University is gratefully acknowledged. <lb/></div>

			<listBibl>■ REFERENCES <lb/>(1) (a) Cordell, G. A. Introduction to Alkaloids: A Biogenetic <lb/>Approach; John Wiley &amp; Sons Inc., 1981. (b) Wearing, X. Z.; Cook, J. <lb/>M. Enantiospecific, Stereospecific Total Synthesis of the Oxindole <lb/>Alkaloid Alstonisine. Org. Lett. 2002, 4, 4237. (c) Yang, J.; Wearing, <lb/>X. Z.; Le Quesne, P. W.; Deschamps, J. R.; Cook, J. M. <lb/>Enantiospecific Synthesis of (+)-Alstonisine via a Stereospecific <lb/>Osmylation Process (1). J. Nat. Prod. 2008, 71, 1431. <lb/>(2) (a) Wright, C. W.; Allen, D.; Cai, Y.; Phillipson, J. D.; Said, I. M.; <lb/>Kirby, G. C.; Warhurst, D. C. In vitro antiamoebic and antiplasmodial <lb/>activities of alkaloids isolated from Alstonia angustifolia roots. <lb/>Phytother. Res. 1992, 6, 121. (b) Wong, W. H.; Lim, P. B.; Chuah, <lb/>C. H. Oxindole alkaloids from Alstonia macrophylla. Phytochemistry <lb/>1996, 41, 313. <lb/>(3) Harada, M.; Ozaki, Y. Effect of Gardneria Alkaloids on <lb/>Ganglionic Transmission in the Rabbit and Rat Superior Cervical <lb/>Ganglia in Situ. Chem. Pharm. Bull. 1978, 26, 48. <lb/>(4) (a) Sakai, S.; Aimi, N.; Kubo, A.; Kitagawa, M.; Shiratori, M.; <lb/>Haginiwa, J. Gardneria alkaloids -VI structures of gardneramine and <lb/>alkaloid G (demethylgardneramine). Tetrahedron Lett. 1971, 12, <lb/>2057. (b) Sakai, S.; Aimi, N.; Kubo, A.; Kitagawa, M.; Hanasawa, M.; <lb/>Katano, K.; Yamaguchi, K.; Haginiwa, J. Structure of Gardneramine <lb/>and 18-Demethylgardneramine. Chem. Pharm. Bull. 1975, 23, 2805. <lb/>(5) Zhang, J.-Y.; Gong, N.; Huang, J.-L.; Guo, L.-C.; Wang, Y.-X. <lb/>Gelsemine, a principal alkaloid from Gelsemium sempervirens Ait., <lb/>exhibits potent and specific antinociception in chronic pain by acting <lb/>at spinal α3 glycine receptors. Pain. 2013, 154, 2452. <lb/>(6) Xu, Y.; Liu, X.; Wang, Y.; Zhou, N.; Peng, J.; Gong, L.; Ren, J.; <lb/>Luo, C.; Luo, X.; Jiang, H.; Chen, K.; Zheng, M. Combinatorial <lb/>Pharmacophore Modeling of Multidrug and Toxin Extrusion <lb/>Transporter 1 Inhibitors: a Theoretical Perspective for Understanding <lb/>Multiple Inhibitory Mechanisms. Sci. Rep. 2015, 5, 13684. <lb/>(7) For selected reviews, see: (a) Galliford, C. V.; Scheidt, K. A. <lb/>Pyrrolidinyl-Spirooxindole Natural Products as Inspirations for the <lb/>Development of Potential Therapeutic Agents. Angew. Chem., Int. Ed. <lb/>2007, 46, 8748. (b) Singh, G. S.; Desta, Z. Y. Isatins As Privileged <lb/>Molecules in Design and Synthesis of Spiro-Fused Cyclic Frame-<lb/>works. Chem. Rev. 2012, 112, 6104. (c) Cheng, D.; Ishihara, Y.; Tan, <lb/>B.; Barbas, C. F. Organocatalytic Asymmetric Assembly Reactions: <lb/>Synthesis of Spirooxindoles via Organocascade Strategies. ACS Catal. <lb/>2014, 4, 743. <lb/>(8) (a) Huang, L.; Miao, H.; Sun, Y.; Meng, F.; Li, X. Discovery of <lb/>indanone derivatives as multi-target-directed ligands against Alz-<lb/>heimer&apos;s disease. Eur. J. Med. Chem. 2014, 87, 429. (b) Menezes, J. C. <lb/>J. M. D. S. Arylidene Indanone Scaffold: Medicinal Chemistry and <lb/>Structure-Activity Relationship View. RSC Adv. 2017, 7, 9357. <lb/>(c) Affini, A.; Hagenow, S.; Zivkovic, A.; Marco-Contelles, J.; Stark, <lb/>H. Novel indanone derivatives as MAO B/H3R dual-targeting ligands <lb/>for treatment of Parkinson&apos;s disease. Eur. J. Med. Chem. 2018, 148, <lb/>487. <lb/>(9) Kamal, M.; Jawaid, T.; Dar, U. A.; Shah, S. A. Chemistry of <lb/>Biologically Potent Natural Products and Synthetic Compounds; Wiley, <lb/>2011; pp 319-337. <lb/>(10) (a) Liu, D.; Liu, X. Y.; Sun, J.; Yan, C. G. Selective Synthesis of <lb/>Diverse Spiro-oxindole-fluorene Derivatives via a DABCO-Promoted <lb/>Annulation Reaction of Bindone and 3-Methyleneoxindoles. J. Org. <lb/>Chem. 2021, 86, 14705. (b) Liu, D.; Liu, X. Y.; Sun, J.; Han, Y.; Yan, <lb/>C. G. Domino reaction of bindone and 1,3-dipolarophiles for the <lb/>synthesis of diverse spiro and fused indeno[1,2-a]fluorene-7,12-<lb/>diones. Org. Biomol. Chem. 2022, 20, 4964. (c) Liu, D.; Sun, J.; Han, <lb/>Y.; Yan, C.-G. Regioselective and Diastereoselective Construction of <lb/>Diverse Dispiro-Indanone-Fluorenone-Oxindole Motifs. J. Org. Chem. <lb/>2023, 88, 17181. <lb/>(11) For a selected review, see: Kaur, J.; Chauhan, P.; Chimni, S. S. <lb/>α,α-Dicyanoolefins: versatile substrates in organocatalytic asymmetric <lb/>transformations. Org. Biomol. Chem. 2016, 14, 7832. <lb/>(12) For selected recent examples, see: (a) Straminelli, L.; Vicentini, <lb/>F.; Di Sabato, A.; Montone, C. M.; Cavaliere, C.; Rissanen, K.; <lb/>Leonelli, F.; Vetica, F. Stereoselective Synthesis of Spiro-Decalin <lb/>Oxindole Derivatives via Sequential Organocatalytic Michael-<lb/>Domino Michael/Aldol Reaction. J. Org. Chem. 2022, 87, 10454. <lb/>(b) Xu, Z.-H.; Jia, S.-K.; Chang, Z.-R.; Hua, Y.-Z.; Wang, M.-C.; Mei, <lb/>G.-J. Facile Access to Saccharin-Fused 1,4-Dihydropyridines through <lb/>[3 + 3] Annulation Reactions. Eur. J. Org. Chem. 2022, 2022, <lb/>No. e202101423. (c) Li, X.; Li, Z.; Zhang, R.; Zhou, Z.; Zhang, Y.; <lb/>Xia, Y.; Yao, W.; Wang, Z. Asymmetric Synthesis of Multicyclic <lb/>Spirooxindole Derivatives Bearing Stereogenic Quaternary Carbon <lb/>Atoms. Org. Lett. 2023, 25, 2642. (d) Nichinde, C. B.; Patil, B. R.; <lb/>Chaudhari, S. S.; Mali, B. P.; Gonnade, R. G.; Kinage, A. K. <lb/>Organocatalysed one-pot three component synthesis of 3,3′-<lb/>disubstituted oxindoles featuring an all-carbon quaternary center <lb/>and spiro[2H-pyran-3,4&apos;-indoline]. RSC Adv. 2023, 13, 13206. <lb/></listBibl>

			<note place="headnote">The Journal of Organic Chemistry <lb/> pubs.acs.org/joc <lb/>Note <lb/></note>

			<note place="footnote">https://doi.org/10.1021/acs.joc.5c00443 <lb/>J. Org. Chem. XXXX, XXX, XXX-XXX <lb/></note>

			<page>H <lb/></page>

			<listBibl>(13) Satham, L.; Sankara, C. S.; Bhagat, S.; Namboothiri, I. N. N. <lb/>Vinylogous Michael addition of nitroalkylideneoxindoles to isatyli-<lb/>dene-malononitriles in the regio-and diastereoselective synthesis of <lb/>dispirocyclopentylbisoxindoles. J. Chem. Sci. 2023, 135, 3. <lb/>(14) (a) Challis, B. C.; Frenkel, A. D. The imidate-amide <lb/>rearrangement: an explanation for the ambident nucleophilic <lb/>properties of neutral amides. J. Chem. Soc., Chem. Commun. 1972, <lb/>303. (b) Kuroda, Y. O-to-N Rearrangement of Allylic Imidates. Synlett <lb/>2022, 33, 98. <lb/>(15) (a) Cramer, F.; Hennrich, N. Imidoester, V. Die Umlagerung <lb/>von Trichloracetimidaten zu N-substituierten Saüreamiden. Chem. <lb/>Ber. 1961, 94, 976. (b) Adhikari, A. A.; Suzuki, T.; Gilbert, R. T.; <lb/>Linaburg, M. R.; Chisholm, J. D. Rearrangement of benzylic <lb/>trichloroacetimidates to benzylic trichloroacetamides. J. Org. Chem. <lb/>2017, 82, 3982. <lb/>(16) (a) Chen, I.-T.; Guan, R.-Y.; Han, J.-L. Asymmetric Sequential <lb/>Vinylogous Mannich/Annulation/Acylation Process of 2-Ethylidene <lb/>1,3-Indandiones and Isatin N-Boc Ketimines: Access to Chiral Spiro-<lb/>Oxindole Piperidine Derivatives. Adv. Synth. Catal. 2022, 364, 2613. <lb/>(b) Lu, T.-Y.; Hsu, W.-Y.; Huang, B.-W.; Han, J.-L. Reagent-<lb/>Controlled Regiodivergent Annulations of Achmatowicz Products <lb/>with Vinylogous Nucleophiles: Synthesis of Bicyclic Cyclopenta[b]-<lb/>pyrans and 8-Oxabicyclo[3.2.1]octane Derivatives. Org. Lett. 2022, <lb/>24, 7806. (c) Kuan, J.-Y.; Chen, I.-T.; Lin, H.; Han, J.-L. <lb/>Organocatalytic Vinylogous Michael Addition/Cyclization Cascade <lb/>of 2-Alkylidene Indane-1,3-diones with Enals: A Regio-and <lb/>Stereocontrolled Diversity-Oriented Route to Indane-1,3-dione <lb/>Derivatives. Adv. Synth. Catal. 2023, 365, 3493. <lb/>(17) For more details, see the Supporting Information. <lb/>(18) Auria-Luna, F.; Marqués-López, E.; Mohammadi, S.; Heiran, <lb/>R.; Herrera, R. P. New Organocatalytic Asymmetric Synthesis of <lb/>Highly Substituted Chiral 2-Oxospiro-[indole-3,4&apos;-(1&apos;,4&apos;-dihydropyr-<lb/>idine)] Derivatives. Molecules 2015, 20, 15807. <lb/>(19) (a) Möhlmann, L.; Chang, G.; Madhusudhan Reddy, G.; Lee, <lb/>C.; Lin, W. Organocatalytic Enantioselective Synthesis of Tetrahydro-<lb/>fluoren-9-ones via Vinylogous Michael Addition/Henry Reaction <lb/>Cascade of 1,3-Indandione-Derived Pronucleophiles. Org. Lett. 2016, <lb/>18, 688. (b) Gao, Y.; Liu, D.; Fu, Z.; Huang, W. Facile Synthesis of <lb/>2,2-Diacyl Spirocyclohexanones via an N-Heterocyclic Carbene-<lb/>Catalyzed Formal [3C + 3C] Annulation. Org. Lett. 2019, 21, 926. <lb/></listBibl>

			<note place="headnote">The Journal of Organic Chemistry <lb/> pubs.acs.org/joc <lb/>Note <lb/></note>

			<note place="footnote">https://doi.org/10.1021/acs.joc.5c00443 <lb/>J. Org. Chem. XXXX, XXX, XXX-XXX <lb/></note>

			<page>I </page>


	</text>
</tei>